**Accelerating biopharmaceutical novelties: Körber joins the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)**

**Lüneburg, Germany / Parsippany, NJ, USA, 14 April 2021. Körber joins the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), a community of biopharma manufacturers who are striving to do groundbreaking research in the field of big data, cell & gene and others to develop manufacturing capabilities in the USA.**

The new membership is an important step to strengthen networks and to achieve closer cooperation in leading biopharmaceutical production innovations. Körber is looking forward to contributing its expertise in areas such as big data and cell & gene therapy, but also creating strong connections with other members of the NIIMBL community that will strengthen advancements in the industry.

“We are happy to welcome Körber, a leading provider of services to the pharmaceutical industry including packaging, inspection and product handling technologies, to the NIIMBL member community. The software products and services portfolio of Körber’s Business Area Pharma, which includes the Werum PAS-X MES manufacturing execution system and the Werum PAS-X Savvy bioprocess data science software, will be a valuable addition to the innovation technologies available through our network,” says Ruben Carbonell, Senior Technology Strategist at NIIMBL.

Rachit Jain, Global Cell and Gene Lead Software at Körber Business Area Pharma, adds: “Continuing our mission to save patient’s lives, we are excited to join NIIMBL in its quest to solve most challenging problems in the biomanufacturing space such as big data and cell & gene therapy initiatives. In this community, Körber will work with community members such as the big pharmas but also with NIST, FDA, and BARDA etc. as we race towards revolutionizing biopharmaceutical manufacturing.”

**Pictures**



Ruben Carbonell, Senior Technology Strategist, NIIMBL



Rachit Jain, Global Cell and Gene Lead Software, Körber Business Area Pharma

**About NIIMBL**

The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is a public-private partnership whose mission is to accelerate biopharmaceutical innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world-leading biopharmaceutical manufacturing workforce, fundamentally advancing U.S. competitiveness in this industry. NIIMBL is part of Manufacturing USA®, a diverse network of federally-sponsored manufacturing innovation institutes, and is funded through a cooperative agreement with the National Institute of Standards and Technology (NIST) in the U.S. Department of Commerce with significant additional support from its members.

<https://niimbl.org>

**Contact**

Chris Yochim

National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)

Business Development Director

Yochim@UDel.edu

**About Körber**

Körber is an international technology group with about 10,000 employees, more than 100 locations worldwide and a common goal: We turn entrepreneurial thinking into customer success and shape the technological change. In the Business Areas Digital, Pharma, Supply Chain, Tissue and Tobacco, we offer products, solutions and services that inspire.

At the Körber Business Area Pharma we are delivering the difference along the pharma value chain with our unique portfolio of integrated solutions. With our software solutions we help drug manufacturers to digitize their pharma, biotech and cell & gene factories. The software product Werum PAS-X MES is recognized as the world’s leading Manufacturing Execution System for the pharma & biotech industry. Our data analytics and AI solutions accelerate product commercialization and uncover hidden business value.

[www.koerber-pharma.com](http://www.koerber-pharma.com/)

**Contact**

Dirk Ebbecke

Körber Business Area Pharma

Head of Global Marketing & Communications Software

Werum IT Solutions GmbH

T: +49 4131 8900-0

E-mail: dirk.ebbecke@koerber-pharma.com